Boston Scientific Corp. of Natick has received European regultory approval for a new cardiac defibrillator, the company announced today.
The implantable device is designed to monitor heartbeats in heart failure patients and improve their response to therapy.
The device, known as LIVIAN CRT-D, is pending approval by the U.S. Food and Drug Administration and is not available in the U.S.
